StreetInsider.com News Articles

Niagen Bioscience: Study links CD38 enzyme to NAD+ decline in aging placental tissue

Mon, 21 Sep 2026 08:32:51 -0400

Niagen Bioscience, Inc. (NASDAQ: NAGE) has highlighted an independent preclinical study published in Nature Communications that identifies the CD38 enzyme as a primary driver of NAD+ decline in aging placental tissue and finds that nicotinamide riboside (NR) improved pregnancy outcomes in aged mice.

The research, led by a team at Sichuan Agricultural University, measured NAD+ and related metabolites in human placental tissue from younger and older mothers. Older placentas contained lower levels of NAD+, NADH, and NADP+. Higher levels of those metabolites were associated with higher infant birth weight. Similar age-related declines were observed in mice and pigs, suggesting the pattern

Niagen Bioscience: Study links CD38 enzyme to NAD+ decline in aging placental tissue

Mon, 21 Sep 2026 08:32:51 -0400

Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (

Mon, 21 Sep 2026 08:32:00 -0400

Preclinical study results showcase that CD38, an NAD-consuming enzyme more active with age and inflammation, leads to NAD+ depletion in placental tissue, while restoring NAD+ with the precursor NR improved placental, fetal, and offspring outcomes in aged mice

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the publication of independent preclinical research in Nature Communications led by a team at Sichuan Agricultural University identifying the CD38 enzyme as a primary

Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (

Mon, 21 Sep 2026 08:32:00 -0400

Canaccord Reiterates Buy Rating on (NAGE)

Fri, 18 Sep 2026 06:43:16 -0400

Canaccord analyst Susan Anderson reiterated a Buy rating and $10.00 price target on (NASDAQ: NAGE).

The analyst commented: "Niagen Bioscience announced the engagement of Red Sky Partners and life sciences executive Martin Hendrix, Ph.D., to help advance its pharmaceutical strategy, including development of NB4168, its investigational small-molecule drug candidate targeting rare genetic diseases and aging-related disorders. The advisory appointments support Niagen’s long-term goal of translating its NAD+ expertise into therapies for rare and orphan diseases with significant unmet medical needs, with an initial focus on Ataxia Telangiectasia (A-T), a rare genetic disease with no FDA approved treatments currently available. The move

Niagen Bioscience adds advisors for drug development push

Thu, 17 Sep 2026 08:32:34 -0400

Niagen Bioscience, Inc. (NASDAQ: NAGE) said its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged life sciences advisory firm Red Sky Partners and independent advisor Martin Hendrix, Ph.D., to support the development of its investigational drug candidate NB4168 and broader corporate strategy.

Red Sky Partners advisors Pauline Jen Ryan and Christopher Kiritsy will focus on drug development, fundraising, strategic transactions, and commercialization. Ryan has nearly four decades of experience advising biotechnology companies and previously served as Senior Vice President of Corporate Development at ImmunoGen, where she helped raise close to $300 million. Kiritsy played a central role in building Kos Pharmaceuticals,

Niagen Bioscience adds advisors for drug development push

Thu, 17 Sep 2026 08:32:34 -0400

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

Thu, 17 Sep 2026 08:32:00 -0400

Advisors bring biotechnology fundraising, drug development, and commercialization, as well as corporate strategy and M&A expertise to support the advancement of NB4168 and strategic corporate growth initiatives

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

Thu, 17 Sep 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

Thu, 17 Sep 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

Thu, 17 Sep 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug

Niagen Bioscience to Present at Canaccord Genuity’s Well Summit

Thu, 10 Sep 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity’s Well Summit, taking place from September 28 to 30, 2026, in New York.

Mr. Fried is scheduled to participate in the Aging on Trial: Peptides, Hormones, and the Line Between Breakthrough and Hype Panel on Tuesday, September 29, from 11:15 a.m. to 12:00 p.m. ET

Niagen Bioscience to Present at Canaccord Genuity’s Well Summit

Thu, 10 Sep 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity’s Well Summit, taking place from September 28 to 30, 2026, in New York.

Mr. Fried is scheduled to participate in the Aging on Trial: Peptides, Hormones, and the Line Between Breakthrough and Hype Panel on Tuesday, September 29, from 11:15 a.m. to 12:00 p.m. ET

Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit

Wed, 26 Aug 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)--

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the Nasdaq X LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, in San Francisco, CA.

Nasdaq is partnering with LD Micro to host 25 curated public companies, each delivering a 15-minute presentation to a room of institutional investors within the Nasdaq San Francisco office. Each presenting company will also participate in dedicated 15-minute breakout sessions immediately following

Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit

Wed, 26 Aug 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)--

Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit

Wed, 26 Aug 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)--

Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit

Wed, 26 Aug 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)--

Canaccord Reiterates Buy Rating on Niagen Bioscience (NAGE)

Mon, 24 Aug 2026 06:41:21 -0400

Canaccord analyst Susan Anderson reiterated a Buy rating and $10.00 price target on Niagen Bioscience (NASDAQ: NAGE).

The analyst commented: "Niagen Bioscience announced that its Tru Niagen NAD+ supplement is now available through GNC and Sam’s Club stores. Management noted the expanded distribution broadens the brand’s retail reach and exposes Tru Niagen to new consumer audiences. CEO Rob Fried noted that the partnerships reflect growing consumer demand for science-backed healthy aging products and further strengthen Tru Niagen’s position in the NAD+ supplement category. NAGE has been slowly expanding into retail doors with first being in Watsons in Hong Kong, Singapore, and

Niagen Bioscience's Tru Niagen now sold at GNC and Sam's Club

Thu, 20 Aug 2026 08:32:15 -0400

Niagen Bioscience, Inc. (NASDAQ: NAGE) announced that its Tru Niagen supplement is now available at GNC and Sam's Club retail locations, as well as on both retailers' e-commerce platforms.

The expansion brings Tru Niagen to nearly 300 retail locations across 44 states combined. At GNC, the product lineup includes Tru Niagen Beauty and Tru Niagen 300mg 30-count bottles, available in store and online. Sam's Club carries Tru Niagen 300mg 120-count bottles in store and online.

"Expanding Tru Niagen across GNC and Sam's Club strengthens our retail footprint and puts the category-leading NAD+ supplement in front of new consumer audiences," said Rob Fried,

Niagen Bioscience's Tru Niagen now sold at GNC and Sam's Club

Thu, 20 Aug 2026 08:32:15 -0400

Niagen Bioscience, Inc. (NASDAQ: NAGE) announced that its Tru Niagen supplement is now available at GNC and Sam's Club retail locations, as well as on both retailers' e-commerce platforms.

"Expanding Tru Niagen across GNC and Sam's Club strengthens our retail footprint and puts the category-leading NAD+ supplement in front of new consumer audiences," said Rob Fried,

Niagen Bioscience's Tru Niagen now sold at GNC and Sam's Club

Thu, 20 Aug 2026 08:32:15 -0400

Niagen Bioscience, Inc. (NASDAQ: NAGE) announced that its Tru Niagen supplement is now available at GNC and Sam's Club retail locations, as well as on both retailers' e-commerce platforms.

"Expanding Tru Niagen across GNC and Sam's Club strengthens our retail footprint and puts the category-leading NAD+ supplement in front of new consumer audiences," said Rob Fried,

Niagen Bioscience's Tru Niagen now sold at GNC and Sam's Club

Thu, 20 Aug 2026 08:32:15 -0400

Niagen Bioscience, Inc. (NASDAQ: NAGE) announced that its Tru Niagen supplement is now available at GNC and Sam's Club retail locations, as well as on both retailers' e-commerce platforms.

"Expanding Tru Niagen across GNC and Sam's Club strengthens our retail footprint and puts the category-leading NAD+ supplement in front of new consumer audiences," said Rob Fried,

Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club

Thu, 20 Aug 2026 08:32:00 -0400

Leading NAD+ healthy aging supplement reaches new health-conscious consumers at nearly 300 GNC and Sam’s Club locations across 44 states combined

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD-boosting supplement in the United States†, is now available at GNC and Sam’s Club retail locations and online at www.gnc.com and www.samsclub.com.

This press release features multimedia. View the full

Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club

Thu, 20 Aug 2026 08:32:00 -0400

Leading NAD+ healthy aging supplement reaches new health-conscious consumers at nearly 300 GNC and Sam’s Club locations across 44 states combined

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD-boosting supplement in the United States†, is now available at GNC and Sam’s Club retail locations and online at www.gnc.com and www.samsclub.com.

This press release features multimedia. View the full

Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club

Thu, 20 Aug 2026 08:32:00 -0400

Leading NAD+ healthy aging supplement reaches new health-conscious consumers at nearly 300 GNC and Sam’s Club locations across 44 states combined

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD-boosting supplement in the United States†, is now available at GNC and Sam’s Club retail locations and online at www.gnc.com and www.samsclub.com.

This press release features multimedia. View the full